Fennec Pharmaceuticals
FENC
68 hedge funds and large institutions have $81.6M invested in Fennec Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 21 increasing their positions, 20 reducing their positions, and 3 closing their positions.
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
6% more funds holding
Funds holding: 64 → 68 (+4)
5% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 20
9.98% less ownership
Funds ownership: 58.51% → 48.53% (-10%)
20% less capital invested
Capital invested by funds: $101M → $81.6M (-$19.9M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$3.36M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$2.32M |
| 3 |
BlackRock
New York
|
+$154K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$114K |
| 5 |
Jane Street
New York
|
+$94.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DG Capital Management
New York
|
-$6.62M |
| 2 |
Morgan Stanley
New York
|
-$320K |
| 3 |
CP
Clayton Partners
Berkeley,
California
|
-$256K |
| 4 |
Goldman Sachs
New York
|
-$180K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$139K |
FENC Hedge Fund Activity: Q1 2025 in Review
68 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q1 2025, worth a combined $81.6M — down 20% from $101M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new FENC positions and 3 closed out — a net gain of 5 holders — while 21 added to existing stakes and 20 trimmed.
The largest buyer was Rosalind Advisors, adding an estimated $3.36M. The largest seller was DG Capital Management, cutting an estimated $6.62M.
- 68 institutional investors held Fennec Pharmaceuticals (FENC) as of Q1 2025, up from 64 in Q4 2024.
- Funds reported $81.6M of Fennec Pharmaceuticals stock for Q1 2025, down 20% quarter-over-quarter.
- 8 funds opened new Fennec Pharmaceuticals positions in Q1 2025 and 3 closed out, a net change of +5 holders.
- The largest Fennec Pharmaceuticals buyer in Q1 2025 was Rosalind Advisors, an estimated $3.36M added.
- The largest Fennec Pharmaceuticals seller in Q1 2025 was DG Capital Management, an estimated $6.62M sold.
Based on aggregated 13F filings for Q1 2025.